Navigation Links
InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
Date:7/13/2009

LOS ALTOS, Calif., July 13 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Geoffrey M. Parker has joined InteKrin as Chief Business Officer. Most recently, Mr. Parker served as a Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. Over the past ten years, Mr. Parker led Goldman Sachs' West Region Healthcare Investment Banking practice during which time he advised many of the biotechnology industry's leading companies.

"We are very pleased to have such an eminent healthcare business professional join us," said Denny Lanfear, InteKrin Chief Executive. "The expertise, insights and depth of business experience Geoff brings are complementary to the InteKrin team's capabilities as world class drug developers and scientists."

"InteKrin is an exciting opportunity and INT131 presents significant promise for patient benefit," said Geoff. "INT131 has the potential to be a breakthrough product, and I am delighted to be part of the InteKrin team as we complete our Phase 2 work and plan to advance into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
2. InteKrin Therapeutics Announces $20 Million Series C Financing
3. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: